myExtraContent1
myExtraContent5

Sep 2013

65. Kongress der Deutschen Gesellschaft für Urologie

VPM participates at the „65. Kongress der Deutschen Gesellschaft für Urologie“ in Dresden on September 25-28, 2013.

BioPharm America 2013

CAP-CMV GmbH participates at the BioPharm 2013 in Boston, MA, USA on September 17-19, 2013.

Peppermint VenturePartners leads seed financing of CAP- CMV, a spin-out company from CEVEC Pharmaceuticals focusing on the development of a novel vaccine for human cytomegalovirus

Peppermint VenturePartners leads seed financing of CAP- CMV, a spin-out company from CEVEC Pharmaceuticals focusing on the development of a novel vaccine for human cytomegalovirus

CAP-CMV GmbH, a company focusing exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection, announced today that it raised a seed financing round of € 0,8 m led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund. Additional financing was provided by NRW.Bank, Creathor Venture, KfW and private investors.

The funds will be used to advance CAP-CMV’s novel vaccine candidate, which consists of HCMV dense bodies (DBs) shed during infection of cells. DBs elicit a strong and lasting humoral and cellular immune response in preclinical models. By nature DBs are not infectious but highly immunogenic, making them an ideal vaccine candidate. Congenital infection with HCMV is a leading cause for neonatal disabilities and also a major health threat to recipients of solid organ or stem transplantations.

CAP-CMV GmbH was established as a joint project between CEVEC Pharmaceuticals GmbH, Vakzine Projekt Management GmbH (VPM) and Prof. Plachter of the University Medical Center Mainz in 2013. The company combines an outstanding experience and proven track record in vaccine development and human cell expression systems and utilizes a unique human cell line expression system (CAP®) to produce the novel vaccine at industrial scale under serum free suspension culture conditions.

Wolfgang Kintzel, Start-Up CEO of CAP-CMV comments: “We are very happy that we could secure an initial financing round for this unique vaccine project with CEVEC’s existing group of investors. The funds will enable us to advance our novel DB vaccine approach to treat and prevent HCMV infections and it provides the basis for a larger financing round in 2014 to advance our program into the clinical development stage.”

Joachim Rautter, Managing Partner at PVP added: “To date nearly all approaches to develop a potent vaccine against HCMV infection failed because of insufficient immune responses or poor efficacy. CAP-CMV aims to solve this unmet medical need by using its DB-based vaccine first in solid-organ transplantation patients and will later address congenital HCMV infections. This makes it a very attractive investment opportunity and we are very much looking forward to work with an experienced and professional team to assure the success of this unique development program.”

About Peppermint VenturePartners: PVP is a Berlin based Venture Capital Company investing in young healthcare companies with a focus on Medical Devices and selected Pharma projects, mainly within Europe, that have successfully demonstrated a first proof-of-concept for their technology, product or services. At the end of 2010 PVP in association with the Charité Foundation launched the new Charité Biomedical Fund (CBF). In the framework of its established collaboration with the Charité – Universitätsmedizin Berlin, PVP has access to the proprietary network and evaluation platform of one of the largest medical schools in Europe and to its international partners. PVP currently manages funds exceeding € 50 million.

Contact:

Peppermint VenturePartners GmbH Dr. Joachim Rautter
Managing Partner
Kurfürstendamm 21

10719 Berlin / Germany Phone: +49 30 590064 411 E-Mail: jr@peppermint-vp.com Homepage: www.peppermint-vp.com

About CAP-CMV GmbH: CAP-CMV GmbH is a spin-out of CEVEC Pharmaceuticals GmbH and focuses exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection. The approach of CAP-CMV is the use of non-infectious “HCMV dense bodies (DBs)”, which is one of the most convincing technology approaches to date. In combination with CEVEC’s unique human cell line expression system (CAP®), the novel vaccine can be produced at industrial scale under serum free suspension culture conditions. With previously demonstrated preclinical efficacy the clinical work plan of the novel vaccine (CAP-CMV-001) aims at solid organ transplantation first and to address the broader indication congenital CMV-infections at a later stage. (CAP-CMV-001) as well as the CAP® cell line technology are both protected by a strong patent portfolio.

About CEVEC Pharmaceuticals GmbH: CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T® expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing its human cell-based expression platform as well as its own “biobetter” candidates through partnerships with renowned pharmaceutical and biotech companies.

Contact:

CAP-CMV GmbH
Wolfgang Kintzel
CEO
Gottfried-Hagen Str. 62
51105 Köln / Germany
Phone: +49 221 46 020804 E-Mail: info@cevec.com Homepage: www.cevec.com
myExtraContent7
myExtraContent8